4-hydroxy-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one | 1034193-41-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-hydroxy-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one
• 英文别名: 4-hydroxy-3,3-dimethyl-1,4-dihydroquinolin-2-one
• CAS: 1034193-41-3
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: FQWDLVXKNQDBCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one 在 二氧化锰 二氯甲烷 作用下， 以 dichloromethane N,N-dimethylformamide 为溶剂， 反应 32.0h， 以yields the title compound as colorless solid (675 mg, yield 69%)的产率得到3,3-二甲基喹啉-2,4-(1H,3H)-二酮
  参考文献：
  名称：

  Organic compounds

  摘要：

  本发明提供了一种I式化合物，该化合物是醛固酮合成酶和/或11beta-羟化酶（CYP11B1）的抑制剂，因此可用于治疗由醛固酮合成酶和/或CYP11B1介导的疾病或疾病。最后，本发明还提供了一种制药组合物。

  公开号：

  US08143278B2
• 作为产物：
  描述：

  3-hydroxy-2,2-dimethyl-3-(2-nitro-phenyl)-propionic acid methyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 4-hydroxy-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  WO2008/76860

  摘要：

  公开号：

文献信息

• ORGANIC COMPOUNDS
  申请人：Hu Qi-Ying

  公开号：US20100093711A1

  公开（公告）日：2010-04-15

  The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase, and/or 11beta-hydroxylase (CYP11B1), and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase and/or CYP11B1. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种I式化合物：所述化合物是醛固酮合成酶和/或11β-羟化酶（CYP11B1）的抑制剂，因此可用于治疗由醛固酮合成酶和/或CYP11B1介导的疾病或疾病。最后，本发明还提供了一种制药组合物。
• Structure–Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors
  作者：Julien P. N. Papillon、Christopher M. Adams、Qi-Ying Hu、Changgang Lou、Alok K. Singh、Chun Zhang、Jose Carvalho、Srinivan Rajan、Adam Amaral、Michael E. Beil、Fumin Fu、Eric Gangl、Chii-Whei Hu、Arco Y. Jeng、Daniel LaSala、Guiqing Liang、Michael Logman、Wieslawa M. Maniara、Dean F. Rigel、Sherri A. Smith、Gary M. Ksander

  DOI：10.1021/acs.jmedchem.5b00407

  日期：2015.6.11

  CYP11B2, the aldosterone synthase, and CYP11B1, the cortisol synthase, are two highly homologous enzymes implicated in a range of cardiovascular and metabolic diseases. We have previously reported the discovery of LCI699, a dual CYP11B2 and CYP11B1 inhibitor that has provided clinical validation for the lowering of plasma aldosterone as a viable approach to modulate blood pressure in humans, as well normalization of urinary cortisol in Cushing's disease patients. We now report novel series of aldosterone synthase inhibitors with single-digit nanomolar cellular potency and excellent physicochemical properties. Structure-activity relationships and optimization of their oral bioavailability are presented. An illustration of the impact of the age of preclinical models on pharmacokinetic properties is also highlighted. Similar biochemical potency was generally observed against CYP11B2 and CYP11B1, although emerging structure-selectivity relationships were noted leading to more CYP11B1-selective analogs.
• 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2121652A1

  公开（公告）日：2009-11-25
• US8143278B2
  申请人：——

  公开号：US8143278B2

  公开（公告）日：2012-03-27
• [EN] 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS<br/>[FR] DÉRIVÉS DE 4-IMIDAZOLYLE-1,2,3,4-TÉTRAHYDROQUINOLINE ET LEUR UTILISATION COMME INHIBITEURS DE L'ALDOSTÉRONE / 11BÊTA-HYDROXYLASE
  申请人：NOVARTIS AG

  公开号：WO2008076860A1

  公开（公告）日：2008-06-26

  [EN] The present invention provides a compound of formula (I), said compound is inhibitor of aldosterone synthase, and/or 11beta-hydroxylase (CYP11B1), and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase and/or CYP11B1. Finally, the present invention also provides a pharmaceutical composition.
  [FR] L'invention concerne un composé de formule (I), qui, en tant qu'inhibiteur de l'aldostérone synthase et/ou de la 11bêta-hydroxylase (CYP11B1), peut servir au traitement d'un trouble ou d'une maladie médiés par l'aldostérone synthase et/ou la CYP11B1. L'invention porte également sur une composition pharmaceutique.